BTG anti-proliferation factor 2 (BTG2)

BTG anti-proliferation factor 2 (BTG2) is a member of the BTG/Tob family of proteins, characterized by its potent anti-proliferative activity [1, 4]. It plays a critical role in regulating the cell cycle, specifically by inducing G1/S phase arrest through the inhibition of cyclin D1 expression and interaction with various transcription factors [2, 3]. BTG2 is a well-documented tumor suppressor; its expression is frequently downregulated in various malignancies, including prostate, breast, and lung cancers, where its loss correlates with poor prognosis and increased tumor aggressiveness [2]. Beyond the cell cycle, BTG2 is involved in DNA damage repair, apoptosis, and cellular differentiation, often acting as a downstream effector of the p53 signaling pathway [1, 2]. While there are currently no FDA-approved drugs that directly bind BTG2, it is considered a significant therapeutic target for re-expression strategies using epigenetic modulators like HDAC inhibitors (e.g., Vorinostat) or through the activation of upstream regulators [2, 3]. Its role as a biomarker is also being explored to predict patient outcomes and response to chemotherapy [2]. References: [1] UniProt (P78543); [2] Mao et al. (2015) Int J Oncol; [3] Winkler (2010) J Cell Physiol; [4] NCBI Gene (7832).

Other names

B-cell translocation gene 2Protein BTG2PC3TIS21NGF-inducible protein TIS21

Transcriptional induction or stabilization of BTG2 protein to inhibit the G1/S transition and promote apoptosis in cancer cells [2, 3]